Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They announced an acquisition in December but didn't announce how big it is. Doing a little digging I found the company that they acquired did $50 million a year in revenue. Revenue for CBDNF will jump from $1 million per year to over $50 million per year. This stock is going to move 10X from here.
$45 million in revenue in 3 years..
Could be $1 million, $4 million, $40 million.
Money talks, bullshit walks. When I read that the CEO put in $5 million I put 100% of my trading account into this at $6. Where to go from here I don't know. I will wait until the shareholder call Aug 16 and decide. If their partner is correct and they can earn $50 million, it is a multiple higher. But bullshit walks. We share see.
Good analysis but double check your fully diluted shares outstanding. With the new investment by Mr. Hawkins I believe the number is substantially higher.
NOTE 18. Subsequent Events
The Company has made a review of material subsequent events from September 30, 2020 through the date of issuance of this report and has determined to
include the following subsequent events:
On December 3, 2020, the Company entered into a Cooperative Research and Development Agreement ( CRADA) with Walter Reed National Military Medical
Center (WRNMMC), the nation’s largest and most renowned joint military medical center serving the Army, Navy, Air Force and Marines located in Bethesda,
Maryland.
A Cooperative Research and Development Agreement ( CRADA) is a written agreement between a government agency and a non-federal entity that allows the
federal government and its non-federal partners to optimize and maximize use of their resources, exchange technical expertise in a protected fashion, share
intellectual property resulting from collaborative effort, and speed commercialization of federally developed technology. The Company has committed to provide
materials including ATCell samples and Umbilical Cord stem cells, ACSelerate Max Growth and differentiation mediums testing and other processing supplies,
processing and testing methods. The Company’s total in-kind and financial commitments are limited to $120,000 in supplies and expense reimbursement during
the life of the Agreement.
The Company maintains the rights to commercialize all technology developed under this CRADA Agreement. The technology is centered on creating in vitro
(test tube) assays to standardize and commercialize new treatment protocols; optimizing quality control measures; and developing standardized protocol potency
assays for precise therapy dosing.
Management believes that these new assays can be commercialized to generate substantial sales and licensing revenues and create value for the Company’s
stakeholders.
Through the Collaboration entitled “Stem Cells for Regeneration and Medical Innovation, a multi-faceted and multi-staged research project with WRNMMC
Biomedical Laboratories, the Company plans to develop, validate and standardize baseline and assay metrics to identify mesenchymal stem cell (MSC)
characteristics and quantities across various cell biomarkers and exosome expressions data sets for its ATCell™ product for biologics developers’ use
worldwide. The focus of the Collaboration is to enable the creation of predictive and prescriptive cellular models which will further enhance American CryoStem’s
mission as a premier biologics’ manufacturer and developer and be highly valuable to the medical community, biotech developers, and the public at large.
WRNMMC is part of The Military Health System (MHS) which is the enterprise within the United States Department of Defense that provides health care to
active duty, Reserve component and retired U.S. Military personnel and their dependents
The missions of the MHS are complex and interrelated: To ensure America’s 1.4 million active duty and 331,000 reserve-component personnel are healthy so
they can complete their national security missions.
· To ensure that all active and reserve medical personnel in uniform are trained and ready to provide medical care in support of operational forces around
the world.
· To provide a medical benefit commensurate with the service and sacrifice of more than 9.5 million active duty personnel, military retirees and their
families.
The MHS also provides health care, through the TRICARE health plan, to:
· active duty service members and their families,
· retired service members and their families,
· Reserve component members and their families,
· surviving family members,
· Medal of Honor recipients and their families
· some former spouses, and
· Others identified as eligible in the Defense Enrollment Eligibility Reporting System.
The MHS has a $50+ billion budget and serves approximately 9.5 million beneficiaries. The MHS employs more than 144,217 in 51 hospitals, 424 clinics, 248
dental clinics and 251 veterinary facilities across the nation and around the world, as well as in contingency and combat-theater operations worldwide.
The Company’s long term research is focused on further developing standardized cellular processing models to support FDA, IND treatment protocol approvals
by further identifying, and validating certain mechanisms and characteristics of mesenchymal stem cells related to regulating modulation of immune response(s)
and promoting tissue regeneration and stability (homeostasis) for the treatment of traumatic injuries, inflammation, auto-immune diseases, and brain and organ
damage associated with viruses such as SARS-CoV-2 (COVID-19), including, the expanding group of people dealing with the chronic and debilitating symptoms
of what is commonly termed “Long Haul COVID” or “Long COVID.”
The Biomedical Research Laboratory in Bethesda, Maryland is Walter Reed Hospital. This is a very big deal.
CRYO Revenues will drop again in the June and Sept quarters. No one is in this for the near term numbers. This is a technology play. The Chinese government just gave their partner $15 million to use CRYO's technology in China. Once it is approved in the US it is worth many times that.
The photos tell the story. This is a very big deal in China. Anyone who thinks it is a fraud should look at these photos.
CRYO invested $300k in Baoxin, which just received about $50 million (US equivalent) from the Chinese government, Since CRYO owns 5% of the company they have turned $300k into a $2.5 million asset. If this is a scam, I hope that they can do more just like it! BTW, Baoxin already has an underwriter to go public on the HK exchange. If they IPO at a $100 million market cap then CRYO has a $5 million asset on the books.
The China deal is very real. Look for them to come back to the US with over $400k. They also own 5% of the Baoxin Ltd, which was just funded for $50 million. Lots of good news now and more coming soon.
Look at the news on Twitter or their Facebook page. "American CryoStem CEO John Arnone attends investment signing ceremony for our Chinese licensee Baoxin with representatives of the China Development Bank at Chinese government offices in Shenzhen China"
Tons of sellers! 85 shares in 90 minutes! Run!
Regarding warning letter: "On January 3, 2018 the Company received a warning letter from the US FDA concerning its contract manufacturing services provided to Cells On Ice. The FDA has informed the Company through the letter that the FDA has determined that its autologous adipose derived cell product ATCELL is a drug under current FDA regulations and guidance and requested that the Company to file an Investigational New Drug (IND) application In response to the letter the Company has ceased shipment of its ATCELL product within the United States and is currently in discussions with the FDA concerning the filing of the Investigational New Drug Application in the near future."
China joint venture spelled out:
"Baoxin will develop, own and operate multiple laboratory/treatment/training facilities in China. The Company has received an upfront fee of $300,000 USD and a 5 year minimum annual guarantee of $500,000 USD per year. Additionally, as part of the transaction the Company has invested $300,000 into Baoxin to obtain 5% minority equity in Baoxin (China) and an option to acquire up to a 20% equity ownership interest in the Regenerative Medicine Center in Hong Kong (HK). The short term goals are to set up two additional GMO grade adipose tissue processing and storage facilities in Beijing and Shanghai to cover the need of the whole China region, and a proper education facility in China to promote the use of ATGRAFT as a more natural dermal filler over artificial fillers."
Earnings are out. Revenue drop is less than I expected. Down about 50% from a year ago. I was expecting worse that that.
Why the anger and bias against this company?
A "Correction" is not an "Admission of deception". The actual quote form the 8k is this...
"Correction of Press Release dated April 5, 2018
The Company today is providing a correction to the description of Cryoviva Ltd. contained in its press release dated April 5, 2018 titled:
“American CryoStem Enters Into Agreement to License its Patented Adipose Tissue and Stem Cell Technologies in Thailand”
The “About Cryoviva” section is updated and corrected to:..."
False and Misleading? That implies intent, especially when YOU throw the word "admits" in front of it. They made a mistake on which certifications the licensee half way around the world has, they discovered the mistake and they corrected it.
Nonsense
They issued a correction in the "About Cryoviva" paragraph. They initially said "Arjun Corp India" rather than "RJ Corp India". BFD.
Monday morning might be interesting. It may same old same old, or it could be explosive upside. They will be meeting hundreds of plastic surgeons over the weekend. If even 10 decide to make a modest investment of $10k in the stock, 100,000 shares could take this to $1.40-$1.50.
I do not have access to a level 2. How much stock do you estimate between here and $1.25? They are going to meet a lot of high income plastic surgeons this weekend. It will only take a couple of buyers to move this stock.
The real news.
In the press release read "About American Cryostem" again. Notice it says office in Bangkok Thailand? Never seen that before have you? Pay attention. There is much more than meets the eye and much more than some naysayers know about.
Stock trading
From "The Caller" March 13, 2018
"Digging deeping into the American Cryostem Corp (CRYO) ‘s technical indicators, we note that the Williams Percent Range or 14 day Williams %R currently sits at -81.82. The Williams %R oscillates in a range from 0 to -100. A reading between 0 and -20 would point to an overbought situation. A reading from -80 to -100 would signal an oversold situation. The Williams %R was developed by Larry Williams. This is a momentum indicator that is the inverse of the Fast Stochastic Oscillator."
China Deal
CRYO now owns 5% of a new company in China. The company is already working with investment bankers in China to go public on the HK exchange. This company will have several clinics in China doing cosmetic surgery, fat grafting and storage, and stem cells. The upside potential over the long term is huge, and CRYO owns 5% of it. This is a big deal.
Understanding China Transaction.
Their Chinese partner paid a $300k licensing fee plus guaranteed to pay a minimum of $500k per year to CRYO. On top of that, the partner is going public on the HK exchange. CRYO will own 5% of that public company. For that 5% they paid $300k. If that company trades at a valuation of $100 million, which is very possible in that market, CRYO will have a $5 million asset. If it only traded at $10 million valuation CRYO has an asset worth $500k. On top of that they will receive a minimum of $500k per year.
This is not a scam at all, but international business as usual. If you think it is a scam just sell your stock and put your money in t-bills. Me, I just keep buying more every month and will continue to do so until CRYO gets bought out by a large biotech. 2019 or 2020 doesn’t matter.
Ater reading the FDA letter a couple of times, basically they need a FTE to monitor and document everything for the FDA. All minor, petty BS with the exception of the need for an IND to be filed. Once CRYO files an IND it will be off to the races once again.
Bought more at $.82. The stock goes down on low volume, up on high volume. Technically it is trading well. I don't expect much until after the first of the year, but I think that $3-$5 next year is very possible.
Closed at $1.12. High $1.30. Low $1.04. There is no resistance up here because it is hitting new all-time highs. Unlike most stocks, nobody is saying "when I get back to even I am selling". It is a thin trader so the next 50,000 share day will probably take it to $1.50.
Someone who doesn't know how to trade a thin stock dumped a large (20,000 shares) market order yesterday. The bad news is it took it down to $.69. The good news is that seller is gone, and some of us got some real bargains yesterday. I bought more and was very impressed how it came back up to $.99.
234,830 shares traded this week. "Volume precedes price".
For the first time that I know of there is a lot of buy orders just below the market. That is good to know that there is very little downside risk from here.
Read the last line. That is the big news. "Arnone added, "To further our effort, American CryoStem plans to file a 510k registration with the FDA for ACSelerate MAX™ registration.""
It was interesting that after the stock dropped 10 cents the selling totally dried up. So basically it was a lack of buying, rather than an abundance of selling that took it down.
It looks like buyers are lining up again. The bid keeps raising. Expect another new soon.
$.59 looks great. So much better that $.29.
It goes up on big volume, down on no volume. You could not ask for better trading action.
Canadian article on stem cells. CRYO should be a $2 stock in the next 12 months.
http://nationalpost.com/news/canada/canadian-clinics-begin-offering-stem-cell-treatments-experts-call-unproven-possibly-unsafe/wcm/f73a696e-a34f-4f4f-9d92-ca8a26707a03
40,000 bid, 11,500 offered. More buyers than sellers, they just don't want to pay up in a thin market. Very smart buyers.
No sellers; The buyers backed away. Look at the volume. It goes up on big volume and down on low.
The way to accumulate a big position in a thin trading stock is this: buy as much as you can without moving the price too much. do it for 2 or 3 days of higher prices then back away and let the sellers come in. Repeat. That is what is happening to CRYO now. Look at the chart and you will see it. Volume is the key.